Ultragenyx Pharmaceutical (RARE) Current Assets (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Current Assets for 14 consecutive years, with $657.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets fell 6.03% year-over-year to $657.0 million; the TTM figure through Mar 2026 stood at $657.0 million (down 6.03% YoY), while the FY2025 annual figure was $951.0 million, up 16.4% from the prior year.
• Current Assets slipped to $657.0 million in Q1 2026 per RARE's latest filing, from $951.0 million in the prior quarter.
• Across five years, Current Assets topped out at $1.0 billion in Q3 2022 and bottomed at $596.0 million in Q1 2024.
• Historically, Current Assets has averaged $760.6 million across 5 years, with a median of $719.8 million in 2025.
• Annual changes were most pronounced in 2023 — Current Assets plunged 40.83% — and 2024, when it jumped 37.39%.
• Ultragenyx Pharmaceutical's Current Assets stood at $883.9 million in 2022, then slipped by 17.16% to $732.2 million in 2023, then climbed by 11.58% to $817.0 million in 2024, then increased by 16.4% to $951.0 million in 2025, then tumbled by 30.91% to $657.0 million in 2026.
• Business Quant data shows RARE's Current Assets at $657.0 million in Q1 2026, $951.0 million in Q4 2025, and $643.2 million in Q3 2025.